Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 million patients with type 2 diabetes.

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.